CD38 as immunomodulator in cancer

被引:19
|
作者
Li, Yanli [1 ]
Yang, Rui [1 ]
Chen, Limo [2 ]
Wu, Sufang [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Shanghai, Peoples R China
[2] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
关键词
biomarker; cancer immunotherapy; CD38; immune checkpoint therapy; immunomodulation; tumor microenvironment; ANTIBODIES TARGETING CD38; MONOCLONAL-ANTIBODIES; BONE-MARROW; ADP-RIBOSE; ANTI-CD38; AUTOANTIBODIES; MULTIPLE-MYELOMA; DENDRITIC CELLS; LUNG-CANCER; EXPRESSION; DARATUMUMAB;
D O I
10.2217/fon-2020-0401
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CD38 is a transmembrane glycoprotein that is widely expressed in a variety of human tissues and cells, especially those in the immune system. CD38 protein was previously considered as a cell activation marker, and today monoclonal antibodies targeting CD38 have witnessed great achievements in multiple myeloma and promoted researchers to conduct research on other tumors. In this review, we provide a wide-ranging review of the biology and function of the human molecule outside the field of myeloma. We focus mainly on current research findings to summarize and update the findings gathered from diverse areas of study. Based on these findings, we attempt to extend the role of CD38 in the context of therapy of solid tumors and expand the role of the molecule from a simple marker to an immunomodulator.
引用
收藏
页码:2853 / 2861
页数:9
相关论文
共 50 条
  • [11] CD38 and Regulation of the Immune Response Cells in Cancer
    Dwivedi, Sanyog
    Rendon-Huerta, Erika P.
    Ortiz-Navarrete, Vianney
    Montano, Luis F.
    JOURNAL OF ONCOLOGY, 2021, 2021
  • [12] CD38 in health and disease
    Bofill, M
    Borthwick, NJ
    HUMAN CD38 AND RELATED MOLECULES, 2000, 75 : 218 - 234
  • [13] CD38 as a Therapeutic Target
    George T Stevenson
    Molecular Medicine, 2006, 12 : 345 - 346
  • [14] CD38 in Neurodegeneration and Neuroinflammation
    Guerreiro, Serge
    Privat, Anne-Laure
    Bressac, Laurence
    Toulorge, Damien
    CELLS, 2020, 9 (02)
  • [15] CD38 in hematopoietic malignancies
    Konopleva, M
    Rissling, I
    Andreeff, M
    HUMAN CD38 AND RELATED MOLECULES, 2000, 75 : 189 - 206
  • [16] CD38 as a therapeutic target
    Stevenson, George T.
    MOLECULAR MEDICINE, 2006, 12 (11-12) : 345 - 346
  • [17] MULTIPLE MYELOMA IN TREATMENT WITH ANTI CD38: NEGATIVIZATION OF CD38 AND OTHER PROGNOSTIC FACTORS
    Zafra Torres, D.
    Diaz Rueda, T.
    Alonso, R.
    Cedena, T.
    Rivero, A.
    Valeri, A.
    La Huerta, J. J.
    Martinez Lopez, J.
    HAEMATOLOGICA, 2017, 102 : 92 - 93
  • [18] Targeting CD38 in Neoplasms and Non-Cancer Diseases
    Szlasa, Wojciech
    Czarny, Jakub
    Sauer, Natalia
    Rakoczy, Katarzyna
    Szymanska, Natalia
    Stecko, Jakub
    Kolodziej, Maksymilian
    Kazmierczak, Maciej
    Barg, Ewa
    CANCERS, 2022, 14 (17)
  • [19] Decreased Expression of CD38 in High Grade Prostate Cancer
    Schmidt, J. I.
    Johnson, A. T.
    Schmechel, S. C.
    LABORATORY INVESTIGATION, 2009, 89 : 192A - 192A
  • [20] Decreased Expression of CD38 in High Grade Prostate Cancer
    Schmidx, J. L.
    Johnson, A. T.
    Schmechel, S. C.
    MODERN PATHOLOGY, 2009, 22 : 192A - 192A